Venus Remedies has said it will commercially launch its new drug ‘Trois’ for the treatment of arthritis in June or July.

The pharma major also said that it is carrying out research on developing innovative drugs for treating viral diseases and immune system enhancing medicines.

“We will launch ‘Trois’ in the month of June or July,” the company Joint Managing Director-cum-Director, Research, Ms Manu Chaudhary, said today.

“This nano technology-based product, Trois, has many advantages, as it has got 178 per cent faster penetration that leads to quick onset of action resulting in enhanced bioavailability, reduction in pain and inflammation associated with arthritis...,” Ms Chaudhary said.

This technology is fully developed and the patent for this technology has already been filed and grants are expected soon, she said.

According to a survey, nearly 70 per cent of people above 65 years of age are suffering from arthritis in India and it would become the biggest epidemic of the country by 2013.

The rheumatoid arthritis drug market in India will be more than double by 2013, growing from $296 million in 2008 to $672 million in 2013.

About one per cent of the world’s population has rheumatoid arthritis. Its market is expected to exceed $23.12 billion by 2015.

Related Topics